Delcath Systems Inc
DCTH - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$714.89M
Close$
$1.07
94.8% downside
Current Fair Value
94.8% downsideOvervalued by 94.8% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $714.89 Million |
|---|---|
| Enterprise Value | $661.76 Million |
| Earnings per Share | $0.08 |
| Beta | 0.6 |
| Outstanding Shares | 36,074,348 |
Return
| Return on Equity | 4.98% |
|---|---|
| Return on Assets | 4.46% |
| Return on Invested Capital | 5.99% |
Valuation & Multiples
| P/E Ratio | 115.45 |
|---|---|
| PEG | 15.65 |
| Price to Sales | 20.55 |
| Price to Book Ratio | 6.85 |
| Enterprise Value to Revenue | 10.3 |
| Enterprise Value to EBIT | 81.15 |
| Enterprise Value to Net Income | 99 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 9, 2026
EPS
$0.17
Est. -$0.09Revenue
$35.10 M
Est. $25.99 MNext Earnings Call
Expected Date
February 25, 2027
EPS Estimate
-$0.10
Consensus analyst estimateRevenue Estimate
$27.28 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 58.06% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 6.33%▼ 42.27% |
|---|---|
| Total Invested | $36.27M▼ 83.54% |
| Investors Holding | 50▼ 79.00% |
About Delcath Systems Inc
CEO: Jennifer Simpson
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product, HEPZATO KIT™ (melphalan hydrochloride for injection/hepatic delivery system), is d...